Loading
A phase 3 trial of Zimberelimab run by Guangzhou Gloria Biosciences Co., Ltd. in cervical cancer, now recruiting.
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT05798819 by Guangzhou Gloria Biosciences Co., Ltd., with 424 participants planned, started 2023-04-20. Conditions listed: Persistent, Recurrent, or Metastatic Cervical Cancer. No results are recorded here; the registry entry is the source.
Shares Zimberelimab, Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares Zimberelimab, Immune checkpoint inhibitors.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares Recurrent or metastatic cervical cancer, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares Recurrent or metastatic cervical cancer, Cervical cancer.